Biodexa Pharmaceuticals PLC
BDRX1.240USD
-0.060-4.62%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
7.68BValor de mercado
7.11P/L TTM
Mais detalhes de Biodexa Pharmaceuticals PLC Empresa
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Informações de Biodexa Pharmaceuticals PLC
Código da empresaBDRX
Nome da EmpresaBiodexa Pharmaceuticals PLC
Data de listagemDec 08, 2014
CEOStamp (Stephen A)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalDec 08
Endereço1 Caspian Point
CidadeABINGDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCF10 4DQ
Telefone4401235888300
Sitehttps://www.biodexapharma.com/
Código da empresaBDRX
Data de listagemDec 08, 2014
CEOStamp (Stephen A)
Executivos da empresa Biodexa Pharmaceuticals PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
Belgium
381.00K
100.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 2 de fev
Atualizado em: seg, 2 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
Outro
96.24%
Investidores
Investidores
Proporção
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
Outro
96.24%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
2.99%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.31%
Hedge Fund
0.07%
Bank and Trust
0.03%
Research Firm
0.02%
Outro
95.63%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
25
26.99K
4.95%
--
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
GAMMA Investing LLC
1.78K
0.29%
+425.00
+31.43%
Dec 31, 2025
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
5.00
0%
-2.00
-28.57%
Sep 30, 2025
Contravisory Investment Management, Inc.
--
0%
-4.00
-100.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
--
0%
-8.00
-100.00%
Apr 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Data
Data ex-dividendo
Tipo
Proporção
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
Ver Mais
